The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases
Abstract
Cardiovascular disease affects approximately 60% of the adult population over the age of 65 and represents the number one cause of death in the United States. Coronary atherosclerosis is responsible for the vast majority of the cardiovascular events, and a number of cardiovascular risk factors have been identified. In recent years, it has become clear that insulin resistance and endothelial dysfunction play a central role in the pathogenesis of atherosclerosis. Much evidence supports the presence of insulin resistance as the fundamental pathophysiologic disturbance responsible for the cluster of metabolic and cardiovascular disorders, known collectively as the metabolic syndrome. Endothelial dysfunction is an important component of the metabolic or insulin resistance syndrome and this is demonstrated by inadequate vasodilation and/or paradoxical vasoconstriction in coronary and peripheral arteries in response to stimuli that release nitric oxide (NO). Deficiency of endothelial‐derived NO is believed to be the primary defect that links insulin resistance and endothelial dysfunction. NO deficiency results from decreased synthesis and/or release, in combination with exaggerated consumption in tissues by high levels of reactive oxygen (ROS) and nitrogen (RNS) species, which are produced by cellular disturbances in glucose and lipid metabolism. Endothelial dysfunction contributes to impaired insulin action, by altering the transcapillary passage of insulin to target tissues. Reduced expansion of the capillary network, with attenuation of microcirculatory blood flow to metabolically active tissues, contributes to the impairment of insulin‐stimulated glucose and lipid metabolism. This establishes a reverberating negative feedback cycle in which progressive endothelial dysfunction and disturbances in glucose and lipid metabolism develop secondary to the insulin resistance. Vascular damage, which results from lipid deposition and oxidative stress to the vessel wall, triggers an inflammatory reaction, and the release of chemoattractants and cytokines worsens the insulin resistance and endothelial dysfunction. From the clinical standpoint, much experimental evidence supports the concept that therapies that improve insulin resistance and endothelial dysfunction reduce cardiovascular morbidity and mortality. Moreover, interventional strategies that reduce insulin resistance ameliorate endothelial dysfunction, while interventions that improve tissue sensitivity to insulin enhance vascular endothelial function. There is general agreement that aggressive therapy aimed simultaneously at improving insulin‐mediated glucose/lipid metabolism and endothelial dysfunction represents an important strategy in preventing/delaying the appearance of atherosclerosis. Interventions that 1 correct carbohydrate and lipid metabolism, 2 improve insulin resistance, 3 reduce blood pressure and restore vascular reactivity, and 4 attenuate procoagulant and inflammatory responses in adults with a high risk of developing cardiovascular disease reduce cardiovascular morbidity and mortality. Whether these benefits hold when the same prevention strategies are applied to younger, high‐risk individuals remains to be determined. Copyright © 2006 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Intensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Self-citationPearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
Celermajer, D. S., Sorensen, K. E., Gooch, V. M., Spiegelhalter, D. J., Miller, O. I., Sullivan, I. D., Lloyd, J. K., & Deanfield, J. E. (1992) · The Lancet · doi:10.1016/0140-6736(92)93147-f · Cited by 4,742
Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
Barnes, P. J., & Karin, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704103361506 · Cited by 4,669
Cited by
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Self-citationRamos, J. S., Dalleck, L. C., Tjonna, A. E., Beetham, K. S., & Coombes, J. S. (2015) · Sports Medicine · doi:10.1007/s40279-015-0321-z · Cited by 715
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Self-citationThe Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547
Inflammation and type 2 diabetes
Calle, M. C., & Fernandez, M. L. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.006 · Cited by 488
Willette, A. A., Bendlin, B. B., Starks, E. J., Birdsill, A. C., Johnson, S. C., Christian, B. T., Okonkwo, O. C., La Rue, A., Hermann, B. P., Koscik, R. L., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0613 · Cited by 418
The cardio-renal-metabolic connection: a review of the evidence
Marassi, M., & Fadini, G. P. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01937-x · Cited by 386
Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling
Nicholls, S. J., Tuzcu, E. M., Kalidindi, S., Wolski, K., Moon, K.-W., Sipahi, I., Schoenhagen, P., & Nissen, S. E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.051 · Cited by 349
Kapogiannis, D., Boxer, A., Schwartz, J. B., Abner, E. L., Biragyn, A., Masharani, U., Frassetto, L., Petersen, R. C., Miller, B. L., & Goetzl, E. J. (2015) · The FASEB Journal · doi:10.1096/fj.14-262048 · Cited by 345
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
Cooper, S. A., Whaley-Connell, A., Habibi, J., Wei, Y., Lastra, G., Manrique, C., Stas, S., & Sowers, J. R. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00522.2007 · Cited by 317
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.013 · Cited by 317
Self-citationMattson, M. P. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.07.003 · Cited by 301
The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance
Traish, A. M., Saad, F., & Guay, A. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.005751 · Cited by 266
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
Does the brain shrink as the waist expands?
Willette, A. A., & Kapogiannis, D. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2014.03.007 · Cited by 162
Caturano, A., Galiero, R., Pafundi, P. C., Cesaro, A., Vetrano, E., Palmiero, G., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108959 · Cited by 73
Markey, O., McClean, C. M., Medlow, P., Davison, G. W., Trinick, T. R., Duly, E., & Shafat, A. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-78 · Cited by 67
Siervo, M., Corander, M., Stranges, S., & Bluck, L. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.10.003 · Cited by 55
Xu, M., Li, X. Y., Wang, J. G., Wang, X. J., Huang, Y., Cheng, Q., Huang, H. E., Li, R., Xiang, J., Tan, J. R., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1386-8 · Cited by 50
Cocoa, Glucose Tolerance, and Insulin Signaling: Cardiometabolic Protection
Grassi, D., Desideri, G., Mai, F., Martella, L., De Feo, M., Soddu, D., Fellini, E., Veneri, M., Stamerra, C. A., & Ferri, C. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b00913 · Cited by 40
Developmental programming of adult haematopoiesis system
Balistreri, C. R., Garagnani, P., Madonna, R., Vaiserman, A., & Melino, G. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100918 · Cited by 28
Chamarthi, B., & Cincotta, A. H. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1315290 · Cited by 25
Vecoli, C., Andreassi, M. G., Liga, R., Colombo, M. G., Coceani, M., Carpeggiani, C., L’Abbate, A., & Neglia, D. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-92 · Cited by 22
Henriksen, E. J. (2014) · Diabetes · doi:10.2337/db14-0057 · Cited by 4
Metadata
- Authors
- Cersosimo, E., & DeFronzo, R. A.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2006-02-28
- Volume
- 22
- Issue
- 6
- Pages
- 423-436
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2072345056
- Cited by
- 525
- References
- 111
- FWCI
- 16.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.